All In MedTech

Device Trial Radar · NCT04577898

RHA® Redensity Eye Versus No-treatment for the Infra-Orbital Hollows

A Randomized, Blinded Evaluator, No-treatment Control, Multicenter, Prospective Clinical Study of RHA® Redensity Eye for the Treatment of Moderate to Severe Tissue Volume Deficiencies in the Infraorbital Regions

Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 248 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

248

Actual

Start

Dec 2, 2020

Primary completion

May 16, 2023

Study completion Feb 14, 2025

Sponsor

Lead sponsor
Teoxane SANot on our public-company list
Sponsor type
Industry
First posted
Oct 8, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, blinded evaluator, randomized, prospective, no treatment control clinical study to identify whether RHA® Redensity Eye (\*) is superior to no treatment for the correction of moderate to severe tissue volume deficiencies in the infraorbital regions. The study will include at least 20% of subjects with Fitzpatrick skin types IV-VI. The Treating Investigator (TI) and the Blinded Live Evaluator (BLE) will evaluate the subject's infraorbital hollows independently of each other using the Teoxane Infraorbital Hollows Scale (TIOHS) at Screening (Visit 1) for eligibility. If the subject is eligible, the BLE's assessment will be used for the Baseline of the primary endpoint. Enrolled subjects will be randomly assigned in a ratio of 3:1 at Screening (Visit 1) to receive RHA® Redensity Eye or to receive no treatment (No-treatment control group). Subjects receiving RHA® Redensity Eye will be further divided by the method of administration (i.e. injection with a 30G ½" needle or 25G 1 ½" cannula), which will be defined for each site at the beginning of the study. Site selection will aim to achieve approximately 1:1 distribution between the administration method subgroups. The BLE will be blinded to the study groups (RHA® Redensity Eye group or No treatment control group). For subjects randomly assigned to RHA® Redensity Eye group, the study will be conducted in 2 Phases - Phase 1a and Phase 2. For subjects randomly assigned to No-treatment control group, the study will be conducted in 3 Phases - Phase 1a, Phase 1b and Phase 2. The Phase 1b is not applicable for the subject assigned to the RHA® Redensity Eye group. (\*): TEO-RHA-1902 was conducted with RHA® Redensity Eye Lido, that contains Lidocaine.

Conditions

  • Infra-orbital Hollows
  • Tear-trough Deformity
  • Wrinkle

Interventions

  • RHA® Redensity EyeDevice

    A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of 1 Point From Baseline in Infra-Orbital Hollows Severity Rated by the Blinded Live Evaluator (BLE) at Week 12 After Last Treatment, Using the TIOHS - Phase 1aTime frame: Period 1 - Phase 1a: Week 12 after last treatment
  2. The Modified FACE-Q "Appearance of Lower Eyelids" Change From Baseline Score for Subjects Treated With RHA® Redensity at Week 12 After Last Treatment - Phase 1aTime frame: Period 1 - Phase 1a: Change from Baseline at Week 12 after last treatment

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • United States, California

    Encino, California

  • United States, Santa Monica

    Santa Monica, California

  • United States, Florida

    Coral Gables, Florida

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.